Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta(2) agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD). This 12-wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Worsley, Sally, Zhu, Chang-Qing, Hardaker, Liz, Church, Alison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545560/
https://www.ncbi.nlm.nih.gov/pubmed/26286141
http://dx.doi.org/10.1186/s12890-015-0092-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545560/
https://www.ncbi.nlm.nih.gov/pubmed/26286141
http://dx.doi.org/10.1186/s12890-015-0092-1

Ejemplares similares